GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Ardent Health Partners Inc (NYSE:ARDT) » Definitions » Research & Development

ARDT (Ardent Health Partners) Research & Development : $0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Ardent Health Partners Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Ardent Health Partners's Research & Development for the three months ended in Dec. 2024 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $0 Mil.

Ardent Health Partners Research & Development Historical Data

The historical data trend for Ardent Health Partners's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardent Health Partners Research & Development Chart

Ardent Health Partners Annual Data
Trend Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial - - - - -

Ardent Health Partners Quarterly Data
Dec16 Sep17 Dec17 Sep18 Dec18 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ardent Health Partners Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardent Health Partners  (NYSE:ARDT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ardent Health Partners Research & Development Related Terms

Thank you for viewing the detailed overview of Ardent Health Partners's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardent Health Partners Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Ardent Health Partners Inc (NYSE:ARDT) » Definitions » Research & Development
Comparable Companies
PACS ADUS SEM ASTH AGL NHC MD USPH GRDN BKD HCA SAU:4013 XTER:FRE SZSE:300015 XKLS:5225 XTER:FME THC UHS BSP:RDOR3 DVA
Traded in Other Exchanges
N/A
Address
340 Seven Springs Way, Suite 100, Brentwood, TN, USA, 37027
Website
https://www.ardenthealth.com
Ardent Health Partners Inc is an operator of hospitals and a provider of healthcare services in the United States. It provide both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. The company has one reportable segment: healthcare services that provides healthcare services primarily through its ownership and operation of hospitals, certain of which provide related healthcare services through physician practices, outpatient centers, and post-acute facilities. Ardent has 30 acute care hospitals, more than 200 sites of care that operates across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas.